Skip to main content

Table 2 Summary of safety data

From: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

AE Total population (n = 27) n (%)
Summary of AEs
 Any AE 26 (96)
 Any AE related to study drug 16 (59)
 Any serious AE 7 (26)
 Any study drug-related serious AE 0
 Death 2 (7)
 Any AE leading to discontinuation 2 (7)
Common AEs (occurring in > 15% of patients)
 Flushing 7 (26)
 Diarrhea 6 (22)
 Infusion-related reaction 6 (22)
 Nasopharyngitis 6 (22)
 Urinary tract infection 6 (22)
 Vomiting 6 (22)
 Wound 6 (22)
 Nausea 5 (19)
AEs related to study drug in > 2 patients
 Infusion-related reaction 6 (22)
 Flushing 6 (22)
 Diarrhea 3 (11)
  1. Abbreviation: AE adverse event